The Affordable Care Act has transformed health care in America both by law and by expanding innovation into a previously less-than-competitive space. Obamacare's state based exchanges are one of the battle grounds where we see traditional insurance heavyweights like UnitedHealth (NYSE: UNH) duke it out against nonprofits and start-ups. However, are these new models, as highlighted by recent stories on Oscar Health Insurance, good for consumers?
The problem comes when customers don't receive what they believed they were promised, regardless if the complaint is valid or not, and Oscar has seen its fair share of complaints. Life isn't easy for any start-up taking on an entrenched system full of well capitalized and well run businesses, let alone one its customer base is counting on working flawlessly every time.
In this episode of Where the Money Is, health care analysts David Williamson and Michael Douglass discuss the latest trends on Obamacare's exchanges, problems with the tech development process in health insurance, and why these are exciting times for investors.
Leaked: This coming blockbuster will make every biotech jealous
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.